CDKN1A and prostate cancer: One of our previous studies indicates the involvement of CDK5 in prostate cancer growth through negatively regulating p21CIP1, a member of the CDK inhibitor family containing conserved N-terminal regions for CDK binding, which suppresses cell cycle progression [67].